Core Viewpoint - The life sciences upstream sector is showing signs of recovery with a year-on-year growth rate of 9.5% in Q1 2025, driven by stable investment and financing, cost reduction, and domestic substitution trends [1] Group 1: Industry Trends - The life sciences upstream sector, which includes instruments, consumables, raw materials, and services, is characterized by specialization, high barriers, and cyclicality [1] - The sector experienced a downturn after rapid growth during the pandemic, but leading companies are expanding and increasing their international presence [1] - Major companies are expected to see a revenue growth rate of 10.75% in 2024, with a significant recovery in Q1 2025 compared to 2023 [1] Group 2: Market Opportunities - The global and Chinese biopharmaceutical markets are thriving, with projections indicating that the Chinese antibody drug market will reach 510.8 billion RMB by 2030 and the CGT market will reach 2.59 billion USD by 2025, providing substantial market growth for the upstream sector [2] - The domestic innovative drug market is heating up, which is likely to accelerate demand for life sciences upstream products [2] Group 3: Domestic Substitution and Innovation - The increasing tariff barriers are enhancing domestic self-sufficiency, allowing local companies to enter major supply chains as cost reduction and supply chain security become more critical [2] - Long-term success in domestic substitution will depend on technological innovation, with local firms increasing R&D investments and moving from low-end to mid-to-high-end products [2] Group 4: Mergers and Acquisitions - Historical analysis of global life sciences giants shows that mergers and acquisitions have been key to their growth, allowing them to focus on core businesses and expand capabilities [3] - Recent favorable policies for mergers and acquisitions, along with the cash-rich status of many life sciences companies, are expected to accelerate consolidation in the sector [3] - Domestic companies are likely to replicate the growth paths of overseas giants through mergers and acquisitions, increasing industry concentration and extending their reach into downstream markets [3]

Core Viewpoint - Shaoyang Hydraulic (301079) has announced a major asset restructuring plan, revealing significant changes in shareholder composition and stock price movements prior to the announcement [1][19]. Shareholder Changes - A new investor named "Li Yuanfang" has emerged as the fifth largest shareholder, holding 724,200 shares, which is 0.66% of the total share capital. This investor was not listed in the previous quarterly report [1][4]. - Another shareholder, "Cao Kangseng," is now the seventh largest shareholder with 537,750 shares, representing 0.49% of the total share capital [3][5]. - Notably, foreign entities Morgan Stanley & Co. International PLC and UBS AG were absent from the latest shareholder list [3][5]. Stock Price Movements - On the trading day before the announcement, Shaoyang Hydraulic's stock price rose by 11.93%, closing at 31.90 CNY per share, compared to 28.50 CNY per share 21 trading days prior [9][19]. - The stock's performance was contrasted with the broader market, where the ChiNext Index fell by 1.74% and the CITIC Machinery Index dropped by 2.62% during the same period [9]. Financial Performance - Shaoyang Hydraulic reported a revenue of 276 million CNY in 2023, a decrease of 8.32% year-on-year, and a net profit of 6.58 million CNY, down 86.88% [16]. - For 2024, the company expects a revenue increase to 351 million CNY, a rise of 27.33%, but a slight decline in net profit to 6.40 million CNY, down 2.76% [16][18]. - The company ranks 142nd out of 213 in total market capitalization within its industry, indicating a relatively weak financial position compared to peers [18]. Asset Acquisition - The target company for the acquisition, Chongqing Xincheng Hangrui Technology Co., Ltd., reported revenues of 353.23 million CNY and 346.65 million CNY for 2023 and 2024, respectively, with net profits of 43.51 million CNY and 30.23 million CNY [14][15]. - The acquisition aims to create synergies and enhance the company's supply chain [14]. Confidentiality Measures - Shaoyang Hydraulic has stated that it has implemented necessary measures to prevent information leakage regarding the asset restructuring and has adhered to confidentiality obligations [10][19].

Group 1 - The year 2025 marks the conclusion of the deepening reform actions for state-owned enterprises, with multiple regions intensifying policies to support mergers and acquisitions of state-owned enterprises [1] - Nanjing Tourism Group is set to integrate with Nanjing Cultural Investment Holding Group and Nanjing Sports Industry Group to create a comprehensive development and operation platform for cultural tourism and sports in Nanjing [1] - The Nanjing municipal government has issued measures to promote high-quality development of mergers and acquisitions, focusing on optimizing equity structure and enhancing operational efficiency [1] Group 2 - Nanjing Tourism Group is advancing a capital injection plan into Nanjing Commercial Tourism Co., which includes acquiring 100% equity of Nanjing Huangpu Grand Hotel through a combination of share issuance and cash payment [2] - The strategic restructuring of Nanjing Commercial Tourism's controlling shareholder aligns with national directives for deepening state-owned enterprise reforms, aiming to enhance the integration of tourism, culture, and sports sectors [2] - The restructuring is expected to significantly influence Nanjing Commercial Tourism's future strategic positioning and business expansion, allowing for the exploration of synergies across industries [2] Group 3 - In addition to the cultural tourism sector, there have been frequent mergers and acquisitions in energy, high-end equipment, and electronic information sectors this year [3] - Inner Mongolia Electric Power Investment Co. announced plans to restructure assets by acquiring 100% equity of Baiyin Hua Coal Power Co. to optimize resource allocation in the region [3] - China Shipbuilding Industry Co. is merging with China Shipbuilding Heavy Industry Co., with the merger approved by the Shanghai Stock Exchange's review committee [3] Group 4 - In the electronic information sector, Guotou Zhonglu Juice Co. plans to acquire 100% equity of China Electronic Engineering Design Institute through share issuance, expanding its business scope beyond juice production [4] - The year 2025 is critical for the deepening reform of state-owned enterprises, emphasizing the need for clear restructuring objectives and effective coordination mechanisms [4]

7月7日晚间，中核科技公告称，公司决定终止发行股份购买西安中核核仪器股份有限公司（以下简称中 核西仪）98.87%股份并募集配套资金的交易事项。 公告显示，中核科技筹划本次交易预计构成重大资产重组与关联交易，并且符合其所处行业通过并购重 组方式强化竞争力的发展趋势。 同时，上述交易是中国核工业集团有限公司（以下简称中核集团）将优质资产注入其控股上市公司的重 要举措。据悉，中核科技与中核西仪均由中核集团控制。 官网显示，中核集团是中央直接管理的特大型国有重要骨干企业，也是国家核科技工业的主体，资产规 模约为1.4万亿元。 市场环境与中核西仪有变 中核科技公告称，公司决定终止本次交易事项，主要是当前市场环境及中核西仪的实际情况，相比于本 次交易的筹划初期发生了一定的变化。 交易预案显示，截至2024年9月30日，中核科技的总资产为26.63亿元，净资产为14.91亿元。 2022年、2023年及2024年前三季度，中核科技的营业收入分别为11.49亿元、13.24亿元、6.63亿元，净 利润分别为1.77亿元、1.64亿元、8159.76万元。 | | | | 单位:万元 | | --- | --- | --- ...

Market Performance - On July 7, 2025, the Shanghai Composite Index rose by 0.02%, while the Shenzhen Component Index fell by 0.70% and the ChiNext Index decreased by 1.21%[3] - The total market turnover was 1,208.497 billion yuan, a decrease of 219.868 billion yuan compared to the previous trading day[3] - Out of 3,286 stocks, 2,010 declined while 1,276 advanced[3] Sector Performance - The top-performing sectors included Comprehensive Finance (up 2.21%), Real Estate (up 1.70%), and Electric Power & Utilities (up 1.50%) while the laggards were Pharmaceuticals (down 0.94%), Communications (down 0.80%), and Home Appliances (down 0.73%)[3][21] - The market style ranking was Stable > Financial > Cyclical > Neutral > Growth > Consumer[21] Capital Flow - On July 7, 2025, the net outflow of main funds was 18.268 billion yuan, with large orders seeing a net outflow of 11.283 billion yuan and small orders experiencing a net inflow of 19.967 billion yuan[4][26] - Southbound capital saw a net inflow of 12.067 billion HKD, with the Shanghai-Hong Kong Stock Connect contributing 5.791 billion HKD and the Shenzhen-Hong Kong Stock Connect contributing 6.276 billion HKD[5][28] ETF Trading - Major ETFs such as the Huaxia SSE 50 ETF and the Huatai-PB CSI 300 ETF saw significant decreases in trading volume, with changes of -7.82 billion yuan and -26.26 billion yuan respectively[4][31] - The total trading volume for ETFs on July 7 was 12.08497 billion yuan, reflecting a decrease from the previous trading day[31] Global Market Overview - On July 7, 2025, major Asia-Pacific indices showed mixed results, with the Hang Seng Index down 0.12% and the Nikkei 225 down 0.56%[5][34] - European indices also experienced declines, with the DAX down 0.61% and the CAC40 down 0.75% on July 4, 2025[5][34]

【 导读 】中核科技终止 筹划重大资产重组，系 市场环境及标的公司 有变 中国基金报记者 闻言 7月7日晚间，中核科技公告称，公司决定终止发行股份购买西安中核核仪器股份有限公司 （以下简称中核西仪）98.87%股份并募集配套资金的交易事项。 公告显示，中核科技筹划本次交易预计构成重大资产重组与关联交易，并且符合其所处行业 通过并购重组方式强化竞争力的发展趋势。 同时，上述交易是中国核工业集团有限公司（以下简称中核集团）将优质资产注入其控股上 市公司的重要举措。据悉，中核科技与中核西仪均由中核集团控制。 官网显示，中核集团是中央直接管理的特大型国有重要骨干企业，也是国家核科技工业的主 体，资产规模约为1.4万亿元。 市场环境与中核西仪有变 中核科技公告称，公司决定终止本次交易事项，主要是当前市场环境及中核西仪的实际情 况，相比 于 本次交易 的 筹划初期发生了 一定的变化。 交易预案显示，截至2024年9月30日，中核科技的总资产为26.63亿元，净资产为14.91亿 元。 2022年、2023年及2024年前三季度，中核科技的营业收入分别为11.49亿元、13.24亿元、 6.63亿元，净利润分别为1.77亿 ...

Mergers and Acquisitions - Hangcha Group's subsidiary plans to increase capital and acquire approximately 99% of Guozhi Robotics [1] - Changhong High-Tech is planning to purchase 100% equity of Guangxi Changke through share issuance and cash payment, which is expected to constitute a major asset reorganization [2] Shareholding Changes - Newray's senior management plans to reduce their holdings by up to 0.3% of the company's shares due to personal financial needs [3] - Zhuoyi Information's employee shareholding platform intends to reduce its holdings by up to 1.88% of the company's shares due to employees' financial needs [4] - Baotong Technology's major shareholders plan to collectively reduce their holdings by up to 2.36% of the company's shares for personal financial reasons [5] Performance Disclosure - Huayou Cobalt expects a year-on-year increase of 56% to 68% in net profit attributable to shareholders for the first half of 2025, driven by integrated operations and rising cobalt prices [6] - Skyworth Digital anticipates a year-on-year decline of 76% to 65% in net profit attributable to shareholders for the first half of 2025 due to a significant drop in sales prices of smart terminal products [7] - Shandong Molong expects a year-on-year decline of 92% to 94% in net profit attributable to shareholders for the first half of 2025, primarily due to the previous year's asset sales [8][9] Investment Matters - Jinhe Biological's wholly-owned subsidiary plans to invest 158 million yuan in a wastewater treatment expansion project to enhance future profitability [10] Risk Matters - Risconda's chairman and a director have been subjected to criminal coercive measures due to allegations of information disclosure violations [11]

比如，百亿级乃至千亿级大规模重大资产重组频现。前述中国船舶吸收合并中国重工即为典型案例，合 并后总资产将超过4000亿元。 再比如，随着监管一再强调鼓励加快上市公司向新质生产力转型步伐，在新增并购重组计划的上市公司 中，涉及半导体，以及计算机、通信和其他电子设备制造业领域的企业数量颇多。典型如华大九天定增 收购芯和半导体100%股权、富乐德定增收购富乐华100%股权、国科微定增收购中芯宁波94.366%股权 等。 另一个值得关注的信号是，在6月18日发布的科创板"1+6"新政中，监管支持上市公司聚焦做优做强主 业，吸收合并上市不满3年的科创板上市公司。在受访人士看来，这或将加速新上市企业的并购重组脚 步。 日前，中国船舶吸收合并中国重工100%股权获上交所审核通过。这是两大超千亿级旗舰造船上市公司 的合并，也是A股有史以来规模最大的上市公司吸收合并。 此次重组完成后，存续公司中国船舶将成为全球最大造船上市公司，资产规模、营业收入规模、手持订 单数均领跑全球。 并购重组，已然成为监管重点鼓励方向。从近期上市公司公告来看，无论是央企国企还是民营企业，并 购重组热情均颇为高涨。 日前，中国船舶吸收合并中国重工100 ...

Core Viewpoint - Jinbo Biological is not merely a cosmetic enterprise but a pioneer in the field of human-derived collagen, with significant technological advancements and market potential in the medical sector [1][12]. Group 1: Company Overview - Jinbo Biological (832982.BJ) announced a deep collaboration with Zhong Shanshan's Yangshengtang, involving a total investment of up to 34 billion yuan, which includes a 20 billion yuan capital increase and a 14.03 billion yuan share transfer [2][3]. - The company holds a 100% market share in the category of three types of medical devices related to collagen [2]. - The founder, Yang Xia, has transformed Jinbo Biological into a leader in the recombinant human collagen market, overcoming significant technical challenges [3][11]. Group 2: Technological Advancements - The company successfully developed the first recombinant type III collagen product in 2014, after years of research and overcoming various technical hurdles [5][6]. - In 2018, Jinbo Biological achieved a breakthrough by synthesizing a unique A-type recombinant type III human collagen with a specific triple helix structure, marking a significant advancement in the field [7][8]. - The company received regulatory approval for its recombinant type III human-derived collagen freeze-dried fiber product in June 2021, establishing it as a leader in the new biological materials sector [8][9]. Group 3: Financial Performance - Jinbo Biological's revenue surged from 233 million yuan in 2021 to 780 million yuan in 2023, reflecting a compound annual growth rate of 82.8% [9][12]. - Net profit increased dramatically from 57.39 million yuan to 732 million yuan, with a cumulative growth exceeding 500% [9]. - The gross margin improved from 82.29% in 2021 to 92.02% in 2023, surpassing that of major competitors [9]. Group 4: Market Position and Future Outlook - The company is positioned to enter the international beauty supply chain, including partnerships with major brands like L'Oréal, enhancing its market reach [9][10]. - Jinbo Biological aims to expand its product line to cover various medical applications, including oral, orthopedic, and gynecological fields, focusing on human tissue repair solutions [11][12]. - The market for recombinant collagen in China is projected to reach 58.6 billion yuan by 2025 and exceed 200 billion yuan by 2030, indicating a significant growth opportunity despite increasing competition [12].

腾讯出手了。 近日，晨壹基金旗下上海晨峦企业管理合伙企业（有限合伙）发生工商变更，新增广西腾讯创业投资有限公司、无锡晨壹成长股权投资基金（有限合伙）、 厦门金圆展鸿二期股权投资合伙企业（有限合伙）、珠海众烨投资企业（有限合伙）等为合伙人。 晨壹基金的掌门人——刘晓丹曾是华泰联合证券的灵魂人物，操刀不少经典案例，被称为"并购女王"。2019年，刘晓丹成立晨壹基金管理（北京）有限公 司，完成私募股权、创业投资基金管理人备案登记，任晨壹基金的管理合伙人，聚焦并购领域。 腾讯出手 天眼查显示，上海晨峦企业管理合伙企业（有限合伙）成立于2022年2月，执行事务合伙人为晨壹红启（北京）咨询有限公司，经营范围含企业管理、企业管 理咨询、信息咨询服务。该合伙企业由晨壹红启（北京）咨询有限公司、北京晨壹并购基金（有限合伙）等共同出资成立。 今年7月，上海晨峦企业管理合伙企业（有限合伙）的合伙人名单新增加了广西腾讯创业投资有限公司、无锡晨壹成长股权投资基金（有限合伙）、厦门金圆 展鸿二期股权投资合伙企业（有限合伙）、珠海众烨投资企业（有限合伙）、深圳舟益管理咨询合伙企业（有限合伙）等，注册资金由4.61亿元增至11.61亿 元。 ...